- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00488878
Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
Data Collection for Patients With Low Grade Ovarian Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To collect, both prospectively and retrospectively, data on disease characterization, treatment, and outcomes for approximately 1600 female patients with low-grade ovarian and peritoneal tumors.
II. To organize clinical information in order to support multifaceted queries of patient characteristics, treatment, and disease outcome data and to facilitate correlation of these characteristics with patient outcome.
III. To have a single data repository, kept on a secure platform that will integrate clinical information and research findings and serve as a secure archive for future research.
SECONDARY OBJECTIVE:
I. To obtain and store human tumor samples in the form of blocks or slides for the purpose of establishing a tumor bank.
OUTLINE:
Patients' medical records are reviewed for retrospective and prospective data collection. Patients may also have residual tissue samples collected and stored.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Lisa Nathan
- Phone Number: 713-745-3837
- Email: lcnathan@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Contact:
- David M. Gershenson
- Phone Number: 713-563-4535
-
Principal Investigator:
- David M. Gershenson
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients whose disease progressed to a higher-grade carcinoma since the time of original diagnosis:
- Ovarian tumor of low malignant potential
- Low-grade serous carcinoma of the ovary
- Primary peritoneal tumor of low malignant potential
- Low-grade serous carcinoma of the peritoneum
- Psammocarcinoma
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observational (electronic health record review)
Patients' medical records are reviewed for retrospective and prospective data collection.
Patients may also have residual tissue samples collected and stored.
|
Medical records are reviewed
Patients' residual tissue samples are collected
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prospective and retrospective data collection on disease characterization, treatment, and outcomes
Time Frame: Up to 28 years
|
Up to 28 years
|
|
Organization of clinical information
Time Frame: Up to 28 years
|
Will be done in order to support multifaceted queries of patient characteristics, treatment, and disease outcome data and to facilitate correlation of these characteristics with patient outcome.
|
Up to 28 years
|
Creation of a single data repository to integrate clinical information and research findings
Time Frame: Up to 28 years
|
Up to 28 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Collection and storage of human tumor samples for the establishment of a tumor bank
Time Frame: Up to 28 years
|
Up to 28 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David M Gershenson, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Cystadenocarcinoma
- Neoplasms, Cystic, Mucinous, and Serous
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Carcinoma
- Adenocarcinoma
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Cystadenocarcinoma, Serous
Other Study ID Numbers
- 2006-0137 (Other Identifier: M D Anderson Cancer Center)
- NCI-2020-13341 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Carcinoma
-
Aivita Biomedical, Inc.Active, not recruitingFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage III Ovarian Carcinoma | Stage IV Ovarian CarcinomaUnited States
-
Women's Hospital School Of Medicine Zhejiang UniversitySun Yat-sen University; Qilu Hospital of Shandong University; Second Affiliated... and other collaboratorsRecruitingEpithelial Ovarian Carcinoma Stage III | Epithelial Ovarian Carcinoma Stage IV | Fallopian Tube Carcinoma Stage III | Fallopian Tube Carcinoma Stage IV | Primary Peritoneal Carcinoma Stage III | Primary Peritoneal Carcinoma Stage IVChina
-
OHSU Knight Cancer InstituteWithdrawnPrimary Peritoneal Carcinoma | Epithelial Ovarian Carcinoma | Ovarian Carcinoma, Stage 3 or 4United States
-
Hospices Civils de LyonCompletedSerous Ovarian Carcinoma | Low Grade Serous Ovarian CarcinomaFrance
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedRecurrent Ovarian Carcinoma | Ovarian Neoplasm | Ovarian Clear Cell Tumor | Adnexal Mass | Ovarian Endometrioid Tumor | Ovarian Serous Tumor | Borderline Ovarian Epithelial TumorUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Recurrent Ovarian Germ Cell Tumor | Undifferentiated Ovarian Carcinoma | Ovarian Serous...United States
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedOvarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnRecurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian CancerUnited States
Clinical Trials on Electronic Health Record Review
-
M.D. Anderson Cancer CenterRecruitingRecurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingMetastatic Malignant Neoplasm in the SpineUnited States
-
Mayo ClinicCompletedMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruiting
-
Mayo ClinicExact Sciences CorporationRecruitingLynch Syndrome | Colorectal CarcinomaUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Cancer-Associated PainUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingPrecision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant ChemotherapyAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Thomas Jefferson UniversityRecruitingLung CarcinomaUnited States
-
M.D. Anderson Cancer CenterRecruitingMetastatic Malignant Neoplasm in the Brain | Central Nervous System Neoplasm | Leptomeningeal Neoplasm | Primary Brain NeoplasmUnited States